Vir Biotechnology, Inc. (VIR) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

9/25

Growth 2 Margin 1 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

9
Vir Biotechnology (VIR) Q2 2026: $315M Astellas Inflow Extends Cash Runway, Sets Stage for Dual Program Milestones
August 06, 2026
11
Veir Biotechnology (VIR) Q1 2026: $1.7B Astellas Deal Accelerates Prostate Cancer Pipeline
May 07, 2026
9
Vir Biotechnology (VIR) Q4 2025: $1.7B Astellas Deal Accelerates Dual-Masked T-Cell Engager Platform
February 25, 2026
10
Vir Biotechnology (VIR) Q3 2025: Accelerated ECLIPSE 1 Enrollment and VIR-5500 Data Update Set Catalysts Into 2027
November 05, 2025
9
Vir Biotechnology (VIR) Q2 2025: Operating Expenses Down $42M as Pipeline Advances Across Three Registration Trials
August 06, 2025
8
Vir Biotechnology (VIR) Q1 2025: $1B Cash Runway Extends Program Push Through 2027
July 04, 2025

Browse all companies